|Bid||0.0000 x 36900|
|Ask||0.0000 x 40000|
|Day's range||1.4400 - 1.6200|
|52-week range||1.4400 - 6.5000|
|Beta (5Y monthly)||3.82|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.33|
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
Like meme stocks will do from time to time, Ocugen (NASDAQ: OCGN) on Wednesday saw a notable price drop a day after a surge. The company was hit by quite a severe price target cut from an analyst, a move that ruined the party after Tuesday's post-earnings run-up. Before market open Wednesday, Noble Capital's Robert LeBoyer made a nearly 40% chop to his Ocugen target.
A third-quarter report, complete with clinical updates, is more than enough to satisfy the biotech's bulls.